

# Wenâ€™Zhao Zhong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6662866/publications.pdf>

Version: 2024-02-01

43  
papers

1,666  
citations

516215

16  
h-index

329751

37  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1749  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 805-815.e3.  | 0.4 | 12        |
| 2  | Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100257.             | 0.6 | 11        |
| 3  | Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. , 2022, 10, e003534.   |     | 56        |
| 4  | Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk. <i>Translational Lung Cancer Research</i> , 2022, 11, 509-522.   | 1.3 | 5         |
| 5  | Intratumoral genetic and immune microenvironmental heterogeneity in <sc>T4N0M0</sc> (diameter≤7Acm) non-small cell lung cancers. <i>Thoracic Cancer</i> , 2022, , .  | 0.8 | 2         |
| 6  | New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019. <i>Journal of Thoracic Oncology</i> , 2022, 17, 588-591.  | 0.5 | 1         |
| 7  | Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 713-722. | 0.8 | 159       |
| 8  | Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100297.  | 0.7 | 4         |
| 9  | Electromagnetic navigation bronchoscopic localization versus percutaneous <sc>CT</sc>-guided localization for thoracoscopic resection of small pulmonary nodules. <i>Thoracic Cancer</i> , 2021, 12, 468-474.                          | 0.8 | 20        |
| 10 | Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. <i>Cancer Communications</i> , 2021, 41, 287-302.  | 3.7 | 74        |
| 11 | Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2021, 10, 1711-1719.   | 1.3 | 4         |
| 12 | Multomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. , 2021, 9, e002312.  |     | 21        |
| 13 | Timing and Origins of Local and Distant Metastases in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1136-1148.  | 0.5 | 39        |
| 14 | Precise resection of multiple pulmonary nodules using a three-dimensional reconstruction model: A case report. <i>Thoracic Cancer</i> , 2021, 12, 970-973.   | 0.8 | 3         |
| 15 | A three-dimensional printing navigational template combined with mixed reality technique for localizing pulmonary nodules. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021, 32, 552-559.                                 | 0.5 | 6         |
| 16 | Genomic signatures define three subtypes of EGFR-mutant stage III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021, 12, 6450.   | 5.8 | 48        |
| 17 | MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. <i>Experimental Hematology and Oncology</i> , 2021, 10, 52.  | 2.0 | 28        |
| 18 | Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives. <i>Cancer Communications</i> , 2021, 41, 1252-1256.  | 3.7 | 8         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers. <i>Annals of Thoracic Surgery</i> , 2020, 109, 856-863.   | 0.7 | 10        |
| 20 | Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. <i>Lung Cancer</i> , 2020, 139, 118-123.   | 0.9 | 33        |
| 21 | 3-dimensional printed navigational template for localizing small pulmonary nodules: A case-controlled study. <i>Thoracic Cancer</i> , 2020, 11, 2690-2697.   | 0.8 | 5         |
| 22 | Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 5822-5832.  | 0.6 | 4         |
| 23 | Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 60, 102990.  | 2.7 | 95        |
| 24 | Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2279-2290.   | 0.8 | 39        |
| 25 | Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1040-1046.  | 0.7 | 16        |
| 26 | Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 3808-3818. | 0.7 | 10        |
| 27 | ASO Author Reflections: Lung Adenocarcinoma with Accidental Invisible Pleural Dissemination Lesions: Wait-and-See Strategy for Tumors with Indolent Biologic Characteristics. <i>Annals of Surgical Oncology</i> , 2020, 27, 3819-3820.        | 0.7 | 0         |
| 28 | Drainage tube hole suture improvement: Removal-free stitches. <i>Thoracic Cancer</i> , 2019, 10, 1827-1833.  | 0.8 | 5         |
| 29 | Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1912-1923.   | 0.5 | 105       |
| 30 | Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1051.  | 1.1 | 6         |
| 31 | Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2235-2245.    | 0.8 | 193       |
| 32 | The superstars of precision medicine—EGFR inhibitors in adjuvant treatment of lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, E11-E13.   | 0.6 | 0         |
| 33 | Application of indocyanine green fluorescence for precision sublobar resection. <i>Thoracic Cancer</i> , 2019, 10, 624-630.  | 0.8 | 21        |
| 34 | Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer — Authors' reply. <i>Lancet Oncology</i> , 2018, 19, e127.  | 5.1 | 2         |
| 35 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–III A (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2018, 19, 139-148.                      | 5.1 | 436       |
| 36 | Prophylactic airway extraction strategy after thoroscopic wedge resection. <i>Thoracic Cancer</i> , 2018, 9, 1406-1412.  | 0.8 | 14        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4929-4937.  | 3.2 | 67        |
| 38 | Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. <i>Chinese Journal of Cancer</i> , 2017, 36, 53. | 4.9 | 5         |
| 39 | The resistance mechanisms and treatment strategies for <i>EGFR</i> -mutant advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 71358-71370.   | 0.8 | 51        |
| 40 | Minimally invasive, multi-disciplinary approach for surgical management of a mediastinal congenital bronchogenic cyst in a 6-month-old infant. <i>Journal of Thoracic Disease</i> , 2017, 9, E743-E747.                                       | 0.6 | 2         |
| 41 | Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. <i>Journal of Thoracic Disease</i> , 2015, 7, 1205-12.  | 0.6 | 11        |
| 42 | Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2015, 7, 1181-8.   | 0.6 | 17        |
| 43 | Lung Cancer Treatment Disparities in China: A Question in Need of an Answer. <i>Oncologist</i> , 2014, 19, 1084-1090.   | 1.9 | 18        |